For instance, if an immunoassay with high LTLV is used to test a patient’s cardiac troponin I (cTnI) levels which is a gold standard biomarker for diagnosing myocardial infarction, it could lead to a wrong diagnosis or inappropriate treatment and ultimate result in a fatal outcome for the patients. This evidence concerns the gene TNNI3 and myocardial infarction.